Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture

Transplant International

Volumn 23, Issue 3, 2010, Pages 259-265

  Toso, Christian ^a   McCall, Michael ^a   Emamaullee, Juliet ^a   Merani, Shaheed ^a   Davis, Joy ^a   Edgar, Ryan ^a   Pawlick, Rena ^a   Kin, Tatsuya ^a   Knudsen, Lotte B ^b   Shapiro, Am James ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Culture; Function; Glucagon; Islet; Pancreas; Peptide

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE;

ADULT; APOPTOSIS; ARTICLE; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENGRAFTMENT; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MALE; PANCREAS ISLET CELL; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GRAFT SURVIVAL; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; TISSUE CULTURE TECHNIQUES; TRANSPLANTATION, HETEROLOGOUS;

EID: 75149152900     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2009.00984.x     Document Type: Article

References (31)

1. Shapiro AM, Lakey Jr, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000 343: 230.
2. Shapiro A, Ricordi C, Hering B, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006 355: 1318.
3. Toso C, Baertschiger R, Morel P, et al. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol. Am J Transplant 2006 6: 1049.
4. Kempf M, Andres A, Morel P, et al. Logistics and transplant coordination activity in the GRAGIL Swiss-French multicenter network of islet transplantation. Transplantation 2005 79: 1200.
5. Kin T, Senior P, O'gorman D, Richer B, Salam A, Shapiro AM. Risk factors for islet loss during culture prior to transplantation. Transpl Int 2008 21: 1029.
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368: 1696.
7. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000 43: 1664.
8. King A, Lock J, Xu G, Bonner-Weir S, Weir GC. Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment. Diabetologia 2005 48: 2074.
9. Sharma A, Sorenby A, Wernerson A, Efendic S, Kumagai-Braesch M, Tibell A. Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes. Diabetologia 2006 49: 1247.
10. Bohman S, Waern I, Andersson A, King A. Transient beneficial effects of exendin-4 treatment on the function of microencapsulated mouse pancreatic islets. Cell Transplant 2007 16: 15.
11. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007 83: 24.
12. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects. Transplantation 2008 86: 36.
13. Faradji RN, Tharavanij T, Messinger S, et al. Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept. Transplantation 2008 86: 1658.
14. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant 2008 8: 1250.
15. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha-and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004 53: 1187.
16. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007 30: 1608.
17. Merani S, Truong W, Emamaullee JA, Toso C, Knudsen LB, Shapiro AM. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves glucose homeostasis in marginal mass islet transplantation in mice. Endocrinology 2008 149: 4322.
18. Emamaullee JA, Merani S, Toso C, et al. Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide. Endocrinology 2009 150: 2145.
19. Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes 1989 38: 140.
20. Barbaro B, Salehi P, Wang Y, et al. Improved human pancreatic islet purification with the refined UIC-UB density gradient. Transplantation 2007 84: 1200.
21. Brandhorst H, Brandhorst D, Hesse F, et al. Successful human islet isolation utilizing recombinant collagenase. Diabetes 2003 52: 1143.
22. Barnett MJ, Ghee-Wilson D, Shapiro AM, Lakey Jr. Variation in human islet viability based on different membrane integrity stains. Cell Transplant 2004 13: 481.
23. Truong W, Emamaullee JA, Merani S, Anderson CC, James Shapiro AM. Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720. Am J Transplant 2007 7: 2031.
24. Toso C, Serre-Beinier V, Emamaullee J, et al. The role of macrophage migration inhibitory factor in mouse islet transplantation. Transplantation 2008 86: 1361.
25. Toso C, Vallee JP, Morel P, et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant 2008 8: 701.
26. Kaufman DB, Gores PF, Field MJ, et al. Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass. Diabetes 1994 43: 778.
27. Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 2005 330: 577.
28. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003 144: 5149.
29. Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005 48: 1339.
30. Ferdaoussi M, Abdelli S, Yang JY, et al. Exendin-4 protects beta-cells from interleukin-1 beta-induced apoptosis by interfering with the c-Jun NH2-terminal kinase pathway. Diabetes 2008 57: 1205.
31. Friedrichsen BN, Neubauer N, Lee YC, et al. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinol 2006 188: 481.